January 10, 2019
Business Wire recently reported that 10X Genomics was ordered to pay $23.9 million in damages for willfully infringing three U.S. patents (patent numbers 8304193, 8329407 and 8889083) owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc. Bio-Rad is a leader in healthcare and life sciences research and is listed on the New York Stock Exchange with ticker symbols BIO and BIOb.
The patents infringed by 10X Genomics are related to Bio-Rad’s droplet microfluidics technologies, such as its Droplet Digital PCR Technology. Bio-Rad President and Chief Executive Officer, Norman Schwartz, stated that “Bio-Rad remains committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research.”
Authors: Sarah Stothart and Alexandra Murray